Great Debates & Updates in

Transcription

1 Great Debates & Updates in Organized for San Francisco, California Chairs William Gradishar, MD, FACP Northwestern University Medical School Chicago, Illinois University of California San Francisco First Announcement W W W. I M E D E X. C O M

2 Great Debates & Updates in Dear Colleague, It is with great pleasure that we invite you to join us for Great Debates and Updates in,, in. Unique and highly interactive, this conference promises to be an exciting two-day educational experience for attendees from all breast cancer-related disciplines. Great Debates and Updates in will feature didactic presentations in conjunction with lively and instructive debates on some of the most challenging topics in breast cancer. Great strides in the area of breast cancer research have been made in recent years, and this meeting is designed to address key aspects of evolving breast cancer therapy including local control and surgical management, genetic profiling and novel biomarkers, optimal implementation of adjuvant therapy, and management of metastatic and resistant disease. Recognized thought leaders give a thorough analysis of all currently available and emerging data, and offer expert insight into the management of breast cancer patients. This meeting will especially highlight the bench to bedside application of this clinical data for your community practice. We hope you will join us in San Francisco for what is sure to be a rewarding experience! Sincerely, William Gradishar, MD, FACP Faculty Benjamin O. Anderson, MD Fred Hutchinson Cancer Research Center Seattle, Washington Scott D. Christensen, MD University of California, Davis Cancer Center Sacramento, California Barbara L. Fowble, MD, FACR, FASTRO UCSF Comprehensive Cancer Center William J. Gradishar, MD, FACP Northwestern University Chicago, Illinois Mohammad Jahanzeb, MD FACP Lynn Cancer Institute West Campus Boca Raton, Florida Virginia Kaklamani, MD, DSc Northwestern University Chicago, Illinois Minetta C. Liu, MD Lombardi Comprehensive Cancer Center and Georgetown University Hospital Washington, District of Columbia Eleftherios Mamounas, MD Aultman Hospital Cancer Center Canton, Ohio Pamela N. Munster, MD University of California, San Francisco University of California, San Francisco Lawrence J. Solin, MD, FACR, FASTRO Albert Einstein Medical Center Philadelphia, Pennsylvania Deborah L. Toppmeyer, MD The Cancer Institute of New Jersey New Brunswick, New Jersey Denise A. Yardley, MD Sarah Cannon Research Institute Nashville, Tennessee

3 Great Debates & Updates in Conference Organizer 4325 Alexander Drive Alpharetta, Georgia , USA Tel.: +1 (770) Fax: +1 (770) Conference Location and Registration Hilton San Francisco Financial District 750 Kearny Street San Francisco, CA Tel.: +1 (415) Fax: +1 (415) The Registration and Information Desk will be staffed: Friday, June 19, :00 am 4:30 pm Saturday, June 20, :00 am 2:30 pm Corporate Support The following companies have provided an educational grant in support of this conference: Silver Genentech BioOncology Bronze Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1 (770) , or by at Continuing Medical Education Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Imedex, LLC designates this educational activity for a maximum 9.75 of AMA PRA Category 1 Credits TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Who Should Attend This educational activity is specifically designed for medical oncologists, radiation oncologists, breast cancer specialists, surgical oncologists, pathologists and other allied healthcare professionals involved in the management of breast cancer. Objectives After successful completion of this educational activity, attendees should be able to: Determine how novel strategies in the surgical management of breast cancer and new recommendations for post-surgery therapy can improve patient outcomes Evaluate whether intense surveillance techniques should be conducted to adequately assess recurrence of risk and individualization of breast cancer therapy Identify the new predictive factors for determining intrinsic resistance for various therapeutic strategies in breast cancer Comment on emerging research in genetic profiling and biomarkers for breast cancer that can influence choice of therapy Interpret and integrate recent clinical trial data on emerging agents for the prevention and treatment of localized and metastatic breast cancer including anti-her2 agents, anti-tubulin agents, and bisphosphonates Summarize optimal hormonal therapy for ER+ stage breast cancer Adequately address controversial questions in the optimal use of anti-her2 agents, including recommendations for early stage HER2+ breast cancer, therapeutic strategies following disease progression, and approaches to combat anti-her2 resistance Please visit for the most up-to-date agenda and to register.

4 Scientific Agenda Friday, May 7, :00 am Welcome and introduction William J. Gradishar, MD, FACP and 9:10 am Pre-meeting audience survey 9:20 am Debate: Should all patients undergo MRI screening prior to surgery? Are all MRI scans the same? Yes: Speaker invited No: Lawrence Solin, MD 9:50 am Debate: Should trastuzumab be recommended for all women with stage I HER2+ breast cancer? Yes: Pamela N. Munster, MD No: William Gradishar, MD 10:20 am Didactic: Is gene expression profiling useful in treatment planning for node positive breast cancer? Deborah L. Toppmeyer, MD 10:40 am Questions and discussion 10:50 am Coffee break 11:10 am Debate: Is continuing trastuzumab in combination with chemotherapy the best treatment strategy following disease progression on trastuzumab? Yes: Scott D. Christensen, MD No: Virginia Kaklamani, MD 11:40 am Didactic: Emerging therapies for targeting HER2-positive breast cancer: current and future directions 12:00 pm Questions and discussion 12:10 pm Lunch break 1:10 pm Debate: Should additional chemotherapy therapy be given for residual disease at the time of surgery following anthracycline and taxane based neoadjuvant chemotherapy? Yes: Mohammad Jahanzeb, MD No: Pamela N. Munster, MD 1:40 pm Debate: Should we recommend post mastectomy radiation to all patients with node positive breast cancer? Yes: Lawrence Solin, MD No: Barbara Fowble, MD 2:10 pm Didactic: BRCA status: impact on therapeutic decision-making Virginia Kaklamani, MD 2:20 pm Questions and discussion 2:40 pm Coffee break 3:00 pm Debate: Can anthracyclines be eliminated as a component of chemotherapy in patients with early stage breast cancer? Yes, 4 cycles of TC is an appropriate substitute: Denise Yardley, MD No, anthracyclines are here to stay: Mohammad Jahanzeb, MD 3:30 pm Didactic: Role of new and emerging chemotherapy agents targeting the microtubule in the treatment of advanced breast cancer. Denise A. Yardley, MD 4:00 pm Questions and discussion 4:10 pm Post-Session audience survey 4:20 pm Adjourn Saturday, May 8, :30 am Introduction William J. Gradishar, MD, FACP and 8:30 am Pre-session audience survey 8:45 am Didactic: Optimal hormonal therapy and symptom management for ERpositive menopausal early stage breast cancer Deborah L. Toppmeyer, MD 9:05 am Debate: Should bevacizumab be continued beyond disease progression? Yes: No: Scott D. Christensen, MD 9:35 am Debate: Should ovarian suppression be routinely prescribed for premenopausal women with high risk early stage breast cancer? Yes: William J. Gradishar, MD, FACP No: Eleftherios Mamounas, MD, MPH 10:05 am Questions and discussion 10:15 am Coffee break 10:35 am Didactic: Evolving use of oncoplastic surgery in the management of breast cancer Benjamin Anderson, MD 10:55 am Debate: Should all patients with de novo stage IV disease have primary breast cancer surgery? Yes: Benjamin Anderson, MD No: Eleftherios Mamounas, MD, MPH 11:25 am Questions and discussion 11:35 am Lunch break 12:35 pm Debate: Bisphosphonates should be routinely used to prevent disease recurrence in women with early stage breast cancer Yes: Scott D. Christensen, MD No: Minetta C. Liu, MD 1:05 pm Didactic: Evolving use of circulating tumor cells and tumor markers in the management of metastatic breast cancer. Minetta C. Liu, MD 1:30 pm Questions and discussion 1:50 pm Post-meeting audience survey 2:00 pm Adjourn

5 Registration Fees Regular... $150 Full/Onsite... $250 Nurses/Residents/Students*... $75 *proof of eligibility must accompany registration *cannot be combined with any other discounts Registration Procedure To Register: You may register online by April 29, 2010 at by calling Imedex at +1 (678) or by returning the registration form in this announcement by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified. Payment: To pre-register, registration and payment must be received no later than April 29, Please register onsite after this date. Contact Imedex at +1 (678) or visit our website at to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received. Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda. Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than April 29, The amount of registration fees remitted, minus a $50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after April 29, Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice. Hotel Accommodations Hilton San Francisco Financial District 750 Kearny Street San Francisco, CA Tel.: +1 (415) Fax: +1 (415) Soaring 27 stories over the City by the Bay, the Hilton San Francisco Financial District hotel offers stunning panoramic views and the perfect location for business or leisure travel. Located in the historic center of the city, the hotel sits at the crossroads of the Financial District, Chinatown, North Beach and Nob Hill. Within bustling, culturally diverse surrounding neighborhoods you are just steps away from San Francisco s most popular attractions such as Alcatraz, Coit Tower, Lombard Street and the Golden Gate Bridge. For premium San Francisco shopping, catch a ride on San Francisco s historic Cable Cars to several locations including Union Square, Embarcadero Center, Westfield Mall, Fisherman s Wharf, Ghirardelli Square and the Ferry Building. For the convenience of attendees, a limited number of rooms have been reserved until April 15, 2010 at a discounted rate of $139 single/double occupancy, plus tax, currently at 14.07% and the San Francisco TID assessment of 1.5%. A $25 per person charge will apply for the third or fourth person per guest room. This rate is not guaranteed outside the conference dates or after April 15, To reserve your room please contact the Hilton Financial District reservations department at or visit the hotel s website at SFOFDHF-IME /index.jhtml?WT. mc_id=pog. To receive the group rate, callers must identify themselves as being with the Great Debates in group. Reservation requests received after April 15, 2010 may not be guaranteed the group rate. Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED. In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual s own physician. Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

6 REGISTRANT INFORMATION REGISTRATION FEES A PAYMENT METHOD CARDHOLDER S NAME SIGNATURE CARD NUMBER EXP. DATE DEGREE: O MD O PhD O PharmD O RN O Other SPECIALTY: O Medical Oncology O Nursing O Radiation Oncology O Surgery O Other FIRST NAME MI LAST NAME ADDRESS TELEPHONE FAX INSTITUTE DEPARTMENT ADDRESS CITY STATE/PROVINCE ZIP/POSTAL CODE COUNTRY O American Express O MasterCard O Visa O Check in the amount of $ O Check if you require special facilities or assistance and attach a note with specific details and requirements Alexander Dr., Alpharetta, GA 30022, USA Great Debates & Updates in Quotes from past participants Very interesting and informative getting pros and cons of treatment and ideas Excellent selection of topics for discussion Enjoyed the juxtaposition of didactic lecture material and well organized debates Maintain the excellent quality of faculty Important Dates Regular Registration Deadline April 29, 2010 Presentation Dates May 7 8, 2010 Regular...O $150 If payment is received by April 29, 2010 Full/Onsite...O $250 If payment is received after April 29, 2010 Nurses/Residents/Students*...O $75 *proof of eligibility must accompany registration To pre-register, registration and payment must be received no later than April 29, Please register onsite after this date. Contact Imedex at +1 (678) or visit our website at to ensure that the meeting is being held as scheduled and to confirm that the meeting is not full. For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than April 29, The amount of registration fees remitted, minus a $50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after April 29, Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda content is subject to change without notice. 25% Imedex is committed to environmental excellence. This publication is printed on FSC-certified paper, which is acid-free and elemental chlorine-free, and contains 50% recycled content including 25% post-consumer waste.